<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; MR</title>
	<atom:link href="http://www.tapanray.in/tag/mr/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Shape of Future Pharma Operations – Emerging A Pragmatic Outlook?</title>
		<link>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shape-of-future-pharma-operations-emerging-a-pragmatic-outlook</link>
		<comments>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/#comments</comments>
		<pubDate>Mon, 12 Apr 2021 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[F2F]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[in-person]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Pragmatic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10468</guid>
		<description><![CDATA[Just as newer reports come almost every day on safety, efficacy, dosage interval or span of immunity of Covid vaccines, similar reports are also reaching us about the possible future shape of pharma sales and marketing operations. Some hardcore optimists, &#8230; <a href="http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Multichannel Marketing: Two Important Pharma Trends</title>
		<link>http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=multichannel-marketing-two-important-pharma-trends</link>
		<comments>http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/#comments</comments>
		<pubDate>Mon, 10 Sep 2018 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[dinner]]></category>
		<category><![CDATA[importance]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCM]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[meetings]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[print]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relevant]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9149</guid>
		<description><![CDATA[On September 6, 2018, Reuters reported the announcement of GlaxoSmithKline (GSK) that it would cut about 650 positions in the United States related to a global restructuring program. This includes 450 Medical (sales) Representatives (MR). Similar announcements on job cuts for MRs &#8230; <a href="http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Digitization or Digitalization: What’s Seen More in Indian Pharma?</title>
		<link>http://www.tapanray.in/digitization-or-digitalization-whats-seen-more-in-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=digitization-or-digitalization-whats-seen-more-in-indian-pharma</link>
		<comments>http://www.tapanray.in/digitization-or-digitalization-whats-seen-more-in-indian-pharma/#comments</comments>
		<pubDate>Sun, 07 Jan 2018 23:48:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[computer]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[digitization]]></category>
		<category><![CDATA[Google]]></category>
		<category><![CDATA[important]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[SAP]]></category>
		<category><![CDATA[Siri]]></category>
		<category><![CDATA[tablet]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8715</guid>
		<description><![CDATA[Just before this New Year, a doctor friend from a large city of India invited me for dinner, as I happened to be there for a couple of days. Dr. Srikanth Kashikar (name changed) is one of my longtime friends, &#8230; <a href="http://www.tapanray.in/digitization-or-digitalization-whats-seen-more-in-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/digitization-or-digitalization-whats-seen-more-in-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Multi-channel Engagement: A New Normal In Pharma Marketing</title>
		<link>http://www.tapanray.in/multi-channel-engagement-a-new-normal-in-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=multi-channel-engagement-a-new-normal-in-pharma-marketing</link>
		<comments>http://www.tapanray.in/multi-channel-engagement-a-new-normal-in-pharma-marketing/#comments</comments>
		<pubDate>Mon, 26 Dec 2016 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[multi]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8021</guid>
		<description><![CDATA[The 2015 Report of AffinityMonitor reconfirms that access to important doctors for pharma Medical Representatives (MRs) continues to decline. Now, fewer than half of all doctors are truly accessible to the MRs, down from nearly 80 percent in 2008. In &#8230; <a href="http://www.tapanray.in/multi-channel-engagement-a-new-normal-in-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/multi-channel-engagement-a-new-normal-in-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Recomposing Notes of Pharma Marketing Playbook</title>
		<link>http://www.tapanray.in/recomposing-notes-of-pharma-marketing-playbook/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=recomposing-notes-of-pharma-marketing-playbook</link>
		<comments>http://www.tapanray.in/recomposing-notes-of-pharma-marketing-playbook/#comments</comments>
		<pubDate>Mon, 20 Jun 2016 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[circle]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[logo]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[Notes]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[Playbook]]></category>
		<category><![CDATA[pull]]></category>
		<category><![CDATA[Push]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Recomposing]]></category>
		<category><![CDATA[representative]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[surrogate]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[vicious]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7680</guid>
		<description><![CDATA[The global management guru Peter Drucker, in one of his management classics &#8211; “The Practice of Management”, published in 1954, that created the discipline of modern management practices, had underscored the following:  “As the core purpose of any business is to &#8230; <a href="http://www.tapanray.in/recomposing-notes-of-pharma-marketing-playbook/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/recomposing-notes-of-pharma-marketing-playbook/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Evolving Scenario of Non-Personal Promotion in Pharma Marketing</title>
		<link>http://www.tapanray.in/evolving-scenario-of-non-personal-promotion-in-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=evolving-scenario-of-non-personal-promotion-in-pharma-marketing</link>
		<comments>http://www.tapanray.in/evolving-scenario-of-non-personal-promotion-in-pharma-marketing/#comments</comments>
		<pubDate>Mon, 28 Sep 2015 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[archaic]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Cash]]></category>
		<category><![CDATA[cocoon]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[cow]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[interactive]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[mature]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[message]]></category>
		<category><![CDATA[monitor]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[Non]]></category>
		<category><![CDATA[NPP]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[practitioners]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[pull]]></category>
		<category><![CDATA[Push]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[restricted]]></category>
		<category><![CDATA[specialists]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7102</guid>
		<description><![CDATA[In the Indian pharmaceutical industry, ‘Non-Personal Promotion (NPP)’ is gradually expected to assume much greater strategic importance than what it is today, if at all, in the overall strategic marketing ball game. This process would get hastened as and when &#8230; <a href="http://www.tapanray.in/evolving-scenario-of-non-personal-promotion-in-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/evolving-scenario-of-non-personal-promotion-in-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Sales Communication: Would ‘Cafeteria Approach’ Be More Productive Today?</title>
		<link>http://www.tapanray.in/pharma-sales-communication-would-cafeteria-approach-be-more-productive-today/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-sales-communication-would-cafeteria-approach-be-more-productive-today</link>
		<comments>http://www.tapanray.in/pharma-sales-communication-would-cafeteria-approach-be-more-productive-today/#comments</comments>
		<pubDate>Mon, 23 Mar 2015 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[applications]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[cafeteria]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[force]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intangible]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medical representatives]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[practitioners]]></category>
		<category><![CDATA[productive]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[SBU]]></category>
		<category><![CDATA[tangible]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tools]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6465</guid>
		<description><![CDATA[For sales communication, quality of access of pharma Medical Representatives (MRs) to many important and busy doctors has been steadily declining over the past several years, all over the world, and India is no exception. This is mainly because the number of &#8230; <a href="http://www.tapanray.in/pharma-sales-communication-would-cafeteria-approach-be-more-productive-today/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-sales-communication-would-cafeteria-approach-be-more-productive-today/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ringside View Of A Key Pharma Job Missing ‘The X Factor&#8217;</title>
		<link>http://www.tapanray.in/ringside-view-of-a-key-pharma-job-missing-the-x-factor/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ringside-view-of-a-key-pharma-job-missing-the-x-factor</link>
		<comments>http://www.tapanray.in/ringside-view-of-a-key-pharma-job-missing-the-x-factor/#comments</comments>
		<pubDate>Mon, 15 Sep 2014 00:00:50 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accreditation]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[Epilogue]]></category>
		<category><![CDATA[Express]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[job]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[profession]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[representative]]></category>
		<category><![CDATA[Ringside]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[view]]></category>
		<category><![CDATA[X-Factor]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5917</guid>
		<description><![CDATA[Just the other day, a well known doctor and a long-time friend of mine invited me for a friendly chat over lunch, after a long while. I had no option really but to accept the invite, as the warmth of his &#8230; <a href="http://www.tapanray.in/ringside-view-of-a-key-pharma-job-missing-the-x-factor/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ringside-view-of-a-key-pharma-job-missing-the-x-factor/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Would e-Marketing Replace Medical Representatives?</title>
		<link>http://www.tapanray.in/would-e-marketing-replace-medical-representatives/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=would-e-marketing-replace-medical-representatives</link>
		<comments>http://www.tapanray.in/would-e-marketing-replace-medical-representatives/#comments</comments>
		<pubDate>Mon, 21 Apr 2014 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Boehringer]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[Eli]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Ingelheim]]></category>
		<category><![CDATA[Lilly]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[nordisk]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Novo]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tools]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5186</guid>
		<description><![CDATA[Many people within the pharmaceutical industry cannot simply visualize a drug marketing environment without Medical Representatives (MRs) detailing their products to doctors for ever increasing prescription support. This much traditional sales force, for face to face interaction and transaction with the &#8230; <a href="http://www.tapanray.in/would-e-marketing-replace-medical-representatives/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/would-e-marketing-replace-medical-representatives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NDDS as New Drug: Good for Patients, Great for Pharma</title>
		<link>http://www.tapanray.in/ndds-as-new-drug-good-for-patients-great-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ndds-as-new-drug-good-for-patients-great-for-pharma</link>
		<comments>http://www.tapanray.in/ndds-as-new-drug-good-for-patients-great-for-pharma/#comments</comments>
		<pubDate>Mon, 13 Jan 2014 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[IND]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[NDA]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rDNA]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4839</guid>
		<description><![CDATA[The Ministry of Health of India has reportedly decided to amend Rule 122 (E) of the Drugs and Cosmetics Rules, 1945 to categorize the New Drug Delivery Systems (NDDS), including ‘Controlled Release (CR)’ or ‘Modified Release (MR)’ formulations, whether a &#8230; <a href="http://www.tapanray.in/ndds-as-new-drug-good-for-patients-great-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ndds-as-new-drug-good-for-patients-great-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
